Insider Selling: Tempus AI, Inc. (NASDAQ:TEM) CAO Sells 339 Shares of Stock

Tempus AI, Inc. (NASDAQ:TEM) CAO Ryan M. Bartolucci sold 339 shares of the business’s stock in a transaction on Monday, December 16th. The shares were sold at an average price of $40.23, for a total transaction of $13,637.97. Following the sale, the chief accounting officer now owns 71,007 shares of the company’s stock, valued at $2,856,611.61. This trade represents a 0.48 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link.

Tempus AI Stock Up 7.6 %

Shares of TEM opened at $35.54 on Friday. The firm’s 50 day simple moving average is $51.70. Tempus AI, Inc. has a 12 month low of $22.89 and a 12 month high of $79.49. The company has a debt-to-equity ratio of 8.17, a current ratio of 2.69 and a quick ratio of 2.55.

Institutional Investors Weigh In On Tempus AI

Several large investors have recently made changes to their positions in the business. NEA Management Company LLC raised its holdings in shares of Tempus AI by 17.8% in the 3rd quarter. NEA Management Company LLC now owns 5,385,979 shares of the company’s stock worth $304,846,000 after purchasing an additional 813,169 shares during the period. Novo Holdings A S bought a new stake in shares of Tempus AI in the second quarter valued at $142,605,000. Revolution Growth Management Company Inc. purchased a new position in shares of Tempus AI during the 2nd quarter valued at $128,133,000. ARK Investment Management LLC grew its stake in shares of Tempus AI by 355.0% during the 3rd quarter. ARK Investment Management LLC now owns 2,378,157 shares of the company’s stock worth $134,604,000 after acquiring an additional 1,855,459 shares during the period. Finally, Alphabet Inc. bought a new position in shares of Tempus AI during the 2nd quarter worth $54,289,000. 24.22% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of research analysts have recently issued reports on the stock. Guggenheim started coverage on shares of Tempus AI in a report on Monday, December 9th. They set a “buy” rating and a $74.00 price objective for the company. Loop Capital lifted their price target on Tempus AI from $48.00 to $57.00 and gave the company a “buy” rating in a research note on Tuesday, October 15th. Stifel Nicolaus downgraded Tempus AI from a “buy” rating to a “hold” rating and increased their price objective for the stock from $45.00 to $65.00 in a research note on Monday, November 11th. Bank of America raised their target price on Tempus AI from $52.00 to $54.00 and gave the company a “neutral” rating in a report on Friday, December 13th. Finally, Piper Sandler reiterated a “neutral” rating and set a $70.00 price target (up previously from $40.00) on shares of Tempus AI in a report on Tuesday, November 12th. Three research analysts have rated the stock with a hold rating and nine have given a buy rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $56.00.

About Tempus AI

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.